Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan, which is notionally held in GSK American Depositary Shares (ADSs). On February 21, 2013, an increase in the notional allocation of ADSs occurred at a price of $44.77 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on the notification of transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on February 21, 2013.
- Share Price: The transaction price was $44.77 per ADS.
- Involved Parties: The notification covers Dr. M M Slaoui (15 ADSs), Dr. K Slaoui (13 ADSs), Mr. W C Louv (23 ADSs), and Mrs. D P Connelly (1 ADS).
- Plan Type: Transactions relate to the US Retirement Savings Plan.